Phase 2 N=11 Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Leukemia
Primary: Recommended Phase II Dose (RP2D) of Bendamustine — 120 mg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=95 Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Hepatitis C
Primary: Percentage of Participants Achieving RVR — 5.6; 75.0; 78.9; 68.8 Percentage of Participants — p=<0.001
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 2 N=494 Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment — 0.03; -0.58; -0.75 percentage of HbA1c — p=<0.0001
Phase 2 N=12 Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 2 N=90 A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
Hepatitis C
Primary: Percentage of Participants Achieving Rapid Viral Response — 86.4; 95.0; 76.2; 20.0 Percentage of participants — p=<0.001
Phase 2 N=5 G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
Lung Cancer
Primary: Number of Patients With Grade 3-4 Febrile Neutropenia During Concurrent Chemoradiotherapy — 0 Participants
Phase 2 N=45 A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
Hepatitis C, Chronic
Primary: Number of Participants Who Experienced an Adverse Event — 21; 23 Participants
Phase 2 N=48 Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Phase 2 N=211 Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d. — 71.1; 84.2; 78.0; 19.0 Percentage of participants — p=<0.001
Phase 2 N=56 Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Determination of the Maximum Tolerated Dose (MTD) of Dasatinib When Given in Combination With Ixabepilone (Phase I) — 100 mg daily
Phase 2 N=210 Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
Neoplasms · Breast Neoplasms · Breast Cancer
Primary: Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel — 2; 1; 2; 0 Number of Dose Limiting Toxicities
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm
Phase 2 N=484 Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Invasive Meningococcal Disease
Primary: Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine. — 90…